Real-world data in 2025 and beyond: Closing the strategy gap

Published on October 22, 2025

Real-world data has already proven its power to transform patient outcomes, accelerate clinical development, and strengthen commercial strategies, but its full value is realized only when pharma organizations approach it with a cohesive, forward-looking strategy. Our white paper, Real-world data in 2025 and beyond: Closing the strategy gap, surveyed 200 life sciences executives to gather […]

Continue reading on website
Other news

The ROI of real-world data: Understanding the current and future state of RWD

October 22, 2025
From clinical trials to regulatory submissions to HEOR research, the value of real-world data (RWD) is clear. So how are today’s pharma leaders using RWD in commercialization strategies, and where are the gaps in realizing its full potential? This infographic reveals the results of Norstella’s survey of 200 life sciences executives about their use of […]

Orion and Abzena Announce Exclusive Commercial License for Abzena’s Antibody

October 23, 2025
San Diego, CA – October 23, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused drug Research and Development (R&D) pi